On 16 June 2005, orphan designation (EU/3/05/293) was granted by the European Commission to GlaxoSmithKline Research & Development Limited, United Kingdom, for nelarabine for the treatment of acute lymphoblastic leukaemia. The sponsorship was transferred to Glaxo Group Limited, United Kingdom, in August 2006.
The sponsorship was transferred toGlaxo Group Limited, United Kingdom, in August 2006 and subsequently to Novartis Europharm Limited, United Kingdom, in April 2015.
Nelarabine has been authorised in the EU as Atriance since 22 August 2007.
|Disease / condition||
Treatment of acute lymphoblastic leukaemia
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.